SCHEMBL725130

SCHEMBL725130

CS(=O)(=O)c1cncc(-c2ccnc3cc(-c4ccc(-c5c[nH]cn5)cc4)oc23)c1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.36
PIK3CG P48736 4/20 0.34
PIK3CB P42338 3/20 0.34
PIK3CD O00329 2/20 0.34
PIK3CA P42336 2/20 0.34
PI4KA P42356 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
CDK2 P24941 1/20 0.32
DYRK1B Q9Y463 1/20 0.32
PTGS2 P35354 4/20 0.31
PTGS1 P23219 2/20 0.31
PRKDC P78527 1/20 0.31
ATR Q13535 1/20 0.31
ATRIP Q8WXE1 1/20 0.31
GPR55 Q9Y2T6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724354 0.82 MAPK1 (0.33) PIK3CA
SCHEMBL725211 0.81 CCNC (0.40) PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA
SCHEMBL722815 0.81 PIK3CA (0.39) PIK3CADYRK1BPRKDC
SCHEMBL15216709 0.80 P4HTM (0.37)
SCHEMBL723677 0.80 TNKS (0.38) PIK3C3PRMT5WDR77
SCHEMBL723480 0.80 PIK3C3 (0.39) PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA
SCHEMBL30765246 0.80 BRD4 (0.40) PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA
SCHEMBL723291 0.79 PIK3C3 (0.36) PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA
SCHEMBL15216703 0.79 PIK3C3 (0.38) PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA
SCHEMBL725049 0.79 PIM1 (0.41) CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PIK3C3 123/4885PIK3CG 959/4885PIK3CB 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.